Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Short-term Renal and Systemic Effects of Dapagliflozin in Non-diabetic Patients With Stage IV CKD at Risk of ESKD Because of Severe Renal Insufficiency and Persistent Proteinuria

NCT04794517 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT04794517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Short-term Renal and Systemic Effects of Dapagliflozin in Non-diabetic Patients With Stage IV CKD at Risk of ESKD Because of Severe Renal Insufficiency and Persistent Proteinuria
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2021
Completion date
May 7, 2024
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases